{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/691baf24b9580981598b479f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Katherine Stueland: The Diagnostic Odyssey Era Ends with Early Genomics","description":"<p>Katherine Stueland’s early advocacy—raising money for genetic disease research as a child—shaped her belief that genomic insight can change lives. As CEO of GeneDx, she has refocused the company on high-need conditions, tripled sequencing capacity, delivered more than 750,000 exomes and genomes, and returned the company to profitability. She highlights the power of combining sequencing with the Infinity database and champions newborn screening, all guided by a core principle: genomic access should reach every family.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p>Audio mixed and mastered by Erick Ziegler</p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p>","author_name":"Inside Precision Medicine"}